Therapeutic Area Market Research Reports & Industry Analysis
Therapeutic areas include Cardiology/Vascular Diseases, Dental and Oral Health, Dermatology, Devices, Endocrinology, Family Medicine, Gastroenterology, Genetic Disease, Healthy Volunteers, Hematology, Hepatology, Immunology, Infections and Infectious Diseases, Internal Medicine, Musculoskeletal, Nephrology, Neurology, Nutrition and Weight Loss, Obstetrics/Gynecology, Oncology, Ophthalmology, Orthopedics/Orthopedic Surgery, Otolaryngology, Pediatrics/Neonatology, Pharmacology/Toxicology, Podiatry, Psychiatry/Psychology, Pulmonary/Respiratory Diseases, Rheumatology, Sleep, Trauma, Urology, and Vaccines.
Reports in these categories will contain statistics of prevalence and growth concerning therapeutic area diseases for which there are product reviews, market size, and share for products that are used in pharmaceutical treatment or equipment that used in surgical treatment of the therapeutic area.
Therapeutic Area Industry Research & Market Reports
-
Cardiovascular and Soft Tissue Repair Patches
... reach US$8.3 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. ePTFE Material, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach ... Read More
-
Cosmetic Dentistry
... CAGR of 6.3% over the analysis period 2024-2030. Dental Systems & Equipment, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.2 Billion by the end of ... Read More
-
Dental Fluoride Treatment
... at a CAGR of 5.2% over the analysis period 2024-2030. Toothpaste, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$4.2 Billion by the end of the ... Read More
-
Disruptive Behavior Disorder (DBD) Treatment
... Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. Oppositional Defiant Disorder, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$19.2 ... Read More
-
Genomics in Cancer Care
... 2030, growing at a CAGR of 16.7% over the analysis period 2024-2030. Genomics Instruments, one of the segments analyzed in the report, is expected to record a 15.4% CAGR and reach US$25.0 Billion by the ... Read More
-
Hemato Oncology Testing
... at a CAGR of 16.5% over the analysis period 2024-2030. Hemato Oncology Testing Services, one of the segments analyzed in the report, is expected to record a 15.6% CAGR and reach US$8.6 Billion by the ... Read More
-
Hyaluronic Acid-based Dermal Fillers
... 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Single Phase Dermal Fillers, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$4.6 Billion ... Read More
-
Interventional Oncology Devices
... at a CAGR of 6.4% over the analysis period 2024-2030. Embolization Devices, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$2.4 Billion by the end of ... Read More
-
Liver Cancer Diagnostics
... at a CAGR of 7.4% over the analysis period 2024-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$9.8 Billion by the end of ... Read More
-
Bariatric (Obesity) Surgical Devices
... 2030, growing at a CAGR of 8.4% over the analysis period 2024-2030. Sleeve Gastrectomy, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$3.6 Billion by the ... Read More
-
Allergy Treatment
... CAGR of 3.7% over the analysis period 2024-2030. Asthma Treatment, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$5.9 Billion by the end of the analysis ... Read More
-
Chronic Obstructive Pulmonary Disease (COPD) Treatment
... reach US$27.8 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Combination Drugs, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach ... Read More
-
Inflammatory Bowel Disease (IBD) Therapeutics
... Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. TNF Inhibitor Drugs, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$14.0 ... Read More
-
Pancreatic Cancer Drugs
... at a CAGR of 4.6% over the analysis period 2024-2030. Exocrine Drugs, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$3.2 Billion by the end of ... Read More
-
Tuberculosis Therapeutics
... CAGR of 2.7% over the analysis period 2024-2030. Active TB Therapeutics, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$654.3 Million by the end of the ... Read More
-
Anxiety Disorder Treatment
... at a CAGR of 2.4% over the analysis period 2024-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$4.9 Billion by the end of the ... Read More
-
Narcolepsy Therapeutics
... CAGR of 7.1% over the analysis period 2024-2030. Narcolepsy with Cataplexy Therapeutics, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$1.9 Billion by the end of ... Read More
-
Metabolic Testing Solutions
... at a CAGR of 6.8% over the analysis period 2024-2030. CPET Systems, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$324.1 Million by the end of ... Read More
-
Liver Cancer Drugs
... at a CAGR of 18.4% over the analysis period 2024-2030. Targeted Drug Therapy, one of the segments analyzed in the report, is expected to record a 18.4% CAGR and reach US$5.1 Billion by the end ... Read More
-
Tinea Pedis (Athlete`s Foot) Treatment
... Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2024-2030. Topical Treatment, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$756.3 Million ... Read More
-
Irritable Bowel Syndrome (IBS) Therapeutics
... Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. IBS-D Therapeutics, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$1.9 Billion ... Read More
-
Peripheral Arterial Disease (PAD) Therapeutics
... Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Peripheral Stents, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$1.8 Billion ... Read More
-
Cancer Immunotherapy
... CAGR of 13.7% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$266.2 Billion by the end of the analysis ... Read More
-
Cancer Stem Cells
... at a CAGR of 8.5% over the analysis period 2024-2030. Stem Cell-based Cancer Therapy, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$1.3 Billion by the ... Read More
-
End-Stage Renal Disease
... at a CAGR of 11.7% over the analysis period 2024-2030. Hemodialysis Treatment, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and reach US$209.9 Billion by the end of ... Read More
Research Assistance
